BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32318337)

  • 1. Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation.
    Mao LJ; Kan Y; Li BH; Ma S; Liu Y; Yang DL; Yang C
    Front Oncol; 2020; 10():421. PubMed ID: 32318337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer.
    Mao LJ; Ding M; Xu K; Pan J; Yu H; Yang C
    J Cancer; 2018; 9(23):4391-4397. PubMed ID: 30519344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer.
    Mao L; Yu H; Ma S; Xu Z; Wei F; Yang C; Zheng J
    J Cancer; 2021; 12(6):1846-1852. PubMed ID: 33613773
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of oncolytic adenovirus ZD55 harboring TRAIL-IETD-MnSOD and cytokine-induced killer cells against lung cancer.
    Jiang R; Zhang Z; Liao X; Huang L; Liao Y; Deng W
    Ann Transl Med; 2021 Oct; 9(20):1527. PubMed ID: 34790733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
    Rajecki M; af Hällström T; Hakkarainen T; Nokisalmi P; Hautaniemi S; Nieminen AI; Tenhunen M; Rantanen V; Desmond RA; Chen DT; Guse K; Stenman UH; Gargini R; Kapanen M; Klefström J; Kanerva A; Pesonen S; Ahtiainen L; Hemminki A
    Int J Cancer; 2009 Nov; 125(10):2441-9. PubMed ID: 19672857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
    Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.
    Mao LJ; Zhang J; Liu N; Fan L; Yang DR; Xue BX; Shan YX; Zheng JN
    Tumour Biol; 2015 Nov; 36(11):9073-81. PubMed ID: 26084613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
    Zhao L; Gu J; Dong A; Zhang Y; Zhong L; He L; Wang Y; Zhang J; Zhang Z; Huiwang J; Qian Q; Qian C; Liu X
    Hum Gene Ther; 2005 Jul; 16(7):845-58. PubMed ID: 16000066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
    Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ
    Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
    Cai Y; Liu X; Huang W; Zhang K; Liu XY
    Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
    Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
    Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus.
    Wang S; Shu J; Chen L; Chen X; Zhao J; Li S; Mou X; Tong X
    Onco Targets Ther; 2016; 9():6381-6388. PubMed ID: 27799786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
    Tong Y; Zhu W; Huang X; You L; Han X; Yang C; Qian W
    Oncol Rep; 2014 Apr; 31(4):1581-8. PubMed ID: 24535016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
    Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
    Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
    Zheng JN; Pei DS; Mao LJ; Liu XY; Sun FH; Zhang BF; Liu YQ; Liu JJ; Li W; Han D
    Cancer Gene Ther; 2010 Jan; 17(1):28-36. PubMed ID: 19498459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma.
    Kim W; Seong J; Oh HJ; Koom WS; Choi KJ; Yun CO
    J Radiat Res; 2011; 52(5):646-54. PubMed ID: 21952320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
    Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X
    Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer.
    Lu M; Wei FK; Wu C; Xu ZY; Mao LJ; Yang DR
    J Oncol; 2022; 2022():7918067. PubMed ID: 35535313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One potential oncolytic adenovirus expressing Lipocalin-2 for colorectal cancer therapy.
    Xu B; Zheng WY; Feng JF; Huang XY; Ge HY
    Cancer Biother Radiopharm; 2013 Jun; 28(5):415-22. PubMed ID: 23464854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells.
    Yuan S; Fang X; Xu Y; Ni A; Liu XY; Chu L
    Oncotarget; 2016 Sep; 7(37):60491-60502. PubMed ID: 27528029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.